NI201000203A - DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa. - Google Patents

DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa.

Info

Publication number
NI201000203A
NI201000203A NI201000203A NI201000203A NI201000203A NI 201000203 A NI201000203 A NI 201000203A NI 201000203 A NI201000203 A NI 201000203A NI 201000203 A NI201000203 A NI 201000203A NI 201000203 A NI201000203 A NI 201000203A
Authority
NI
Nicaragua
Prior art keywords
inhibitors
tafia
sulfamide
derivatives
macrocyclic urea
Prior art date
Application number
NI201000203A
Other languages
English (en)
Spanish (es)
Inventor
Kallus Christopher
Wagner Michael
Broenstrup Mark
Evers Andreas
Globisch Anja
Schreuder Herman
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI201000203A publication Critical patent/NI201000203A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NI201000203A 2008-06-06 2010-11-22 DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa. NI201000203A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06

Publications (1)

Publication Number Publication Date
NI201000203A true NI201000203A (es) 2011-09-29

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000203A NI201000203A (es) 2008-06-06 2010-11-22 DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa.

Country Status (34)

Country Link
US (5) US8580777B2 (cg-RX-API-DMAC7.html)
EP (1) EP2300462B1 (cg-RX-API-DMAC7.html)
JP (1) JP5531011B2 (cg-RX-API-DMAC7.html)
KR (1) KR101673886B1 (cg-RX-API-DMAC7.html)
CN (1) CN102056922B (cg-RX-API-DMAC7.html)
AR (1) AR072007A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009254257B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0913349A2 (cg-RX-API-DMAC7.html)
CA (1) CA2726554C (cg-RX-API-DMAC7.html)
CL (1) CL2009001358A1 (cg-RX-API-DMAC7.html)
CO (1) CO6321271A2 (cg-RX-API-DMAC7.html)
CR (1) CR11807A (cg-RX-API-DMAC7.html)
CY (1) CY1115604T1 (cg-RX-API-DMAC7.html)
DK (1) DK2300462T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2010000363A (cg-RX-API-DMAC7.html)
EC (1) ECSP10010655A (cg-RX-API-DMAC7.html)
ES (1) ES2494390T3 (cg-RX-API-DMAC7.html)
HN (1) HN2010002558A (cg-RX-API-DMAC7.html)
HR (1) HRP20140787T1 (cg-RX-API-DMAC7.html)
IL (1) IL209772A (cg-RX-API-DMAC7.html)
MA (1) MA32322B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010012793A (cg-RX-API-DMAC7.html)
NI (1) NI201000203A (cg-RX-API-DMAC7.html)
NZ (1) NZ589671A (cg-RX-API-DMAC7.html)
PL (1) PL2300462T3 (cg-RX-API-DMAC7.html)
PT (1) PT2300462E (cg-RX-API-DMAC7.html)
RU (1) RU2502736C2 (cg-RX-API-DMAC7.html)
SI (1) SI2300462T1 (cg-RX-API-DMAC7.html)
SV (1) SV2010003747A (cg-RX-API-DMAC7.html)
TW (1) TWI455928B (cg-RX-API-DMAC7.html)
UA (1) UA104002C2 (cg-RX-API-DMAC7.html)
UY (1) UY31868A (cg-RX-API-DMAC7.html)
WO (1) WO2009146802A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007719B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2494390T3 (es) 2008-06-06 2014-09-15 Sanofi Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa
AU2009263076B2 (en) 2008-06-23 2012-07-26 Astrazeneca Ab New heterocyclic carboxamides for use as thrombin inhibitors
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
ME02630B (me) * 2012-03-06 2017-06-20 Pfizer Makrociklički derivati, namijenjeni liječenju proliferativnih bolesti
EP3027611B1 (en) * 2013-06-10 2017-07-26 Sanofi Macrocyclic urea derivatives as inhibitors of tafi a, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
CA2298601A1 (en) 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
AU2007327959B2 (en) 2006-12-06 2013-08-01 Sanofi-Aventis Urea and sulfamide derivatives as tafia inhibitors
ES2494390T3 (es) 2008-06-06 2014-09-15 Sanofi Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa

Also Published As

Publication number Publication date
MX2010012793A (es) 2010-12-14
RU2010154089A (ru) 2012-07-20
US9126955B2 (en) 2015-09-08
IL209772A0 (en) 2011-02-28
KR101673886B1 (ko) 2016-11-08
DOP2010000363A (es) 2010-12-15
AU2009254257A1 (en) 2009-12-10
CA2726554A1 (en) 2009-12-10
US20140039011A1 (en) 2014-02-06
RU2502736C2 (ru) 2013-12-27
EP2300462B1 (de) 2014-05-21
US20160251324A1 (en) 2016-09-01
CN102056922B (zh) 2013-11-20
ES2494390T3 (es) 2014-09-15
US9688645B2 (en) 2017-06-27
CA2726554C (en) 2015-02-24
HN2010002558A (es) 2012-08-28
EP2300462A1 (de) 2011-03-30
AR072007A1 (es) 2010-07-28
WO2009146802A1 (de) 2009-12-10
US20110178130A1 (en) 2011-07-21
US20140206760A1 (en) 2014-07-24
US8580777B2 (en) 2013-11-12
KR20110020795A (ko) 2011-03-03
PL2300462T3 (pl) 2014-10-31
JP5531011B2 (ja) 2014-06-25
IL209772A (en) 2016-04-21
ZA201007719B (en) 2011-07-27
SI2300462T1 (sl) 2014-09-30
NZ589671A (en) 2012-03-30
TWI455928B (zh) 2014-10-11
UY31868A (es) 2010-01-05
JP2011521981A (ja) 2011-07-28
UA104002C2 (ru) 2013-12-25
ECSP10010655A (es) 2011-01-31
US20160024033A1 (en) 2016-01-28
HK1152936A1 (en) 2012-03-16
CN102056922A (zh) 2011-05-11
CO6321271A2 (es) 2011-09-20
MA32322B1 (fr) 2011-05-02
CY1115604T1 (el) 2017-01-04
SV2010003747A (es) 2011-03-15
PT2300462E (pt) 2014-08-05
AU2009254257B2 (en) 2013-11-21
TW201008917A (en) 2010-03-01
HRP20140787T1 (hr) 2014-11-21
US8722655B2 (en) 2014-05-13
US9309207B2 (en) 2016-04-12
CL2009001358A1 (es) 2009-11-27
DK2300462T3 (da) 2014-08-18
CR11807A (es) 2011-02-16
BRPI0913349A2 (pt) 2015-11-24

Similar Documents

Publication Publication Date Title
NI201000203A (es) DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa.
MX2018006148A (es) Inhibidores de cxcr2.
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
CR20110440A (es) Compuestos de piridazinona
BR112013021896A2 (pt) inibidores de serina/treonina cinase
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
CR20130024A (es) Compuestos heterocíclicos fusionados
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
MD3237406T2 (ro) Derivați ai 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-dionei în calitate de inhibitori ai ADAMTS pentru tratamentul osteoartritei
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX374439B (es) Compuesto de piridona como inhibidor de c-met
NI200600217A (es) Derivados de imidazol utilizados como inhibidores de tafia
NO20092246L (no) Urea og sulfamidderivater som tafiainhibitorer
CR20140564A (es) Derivados de pirimidinona como agentes antimaláricos
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
CL2012001606A1 (es) Compuestos derivados de tiazoles bicíclicos como moduladores alostéricos de receptores mglur5; composición farmacéutica que los comprende; procedimiento de preparación de la composición farmacéutica; combinación farmacéutica; y uso del compuesto en la prevención, tratamiento o profilaxis de trastornos neurológicos o psiquiátricos.
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa